SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effectsdoi:10.3390/MEDICINA55060268Carlo GarofaloSilvio BorrelliMaria Elena LibertiMichele AndreucciGiuseppe ConteRoberto MinutoloMichele ProvenzanoLuca De NicolaMedicina (Kaunas)
The domestic diabetes treatment market will likely undergo fierce competition as new SGLT-2 inhibitors, including the generic products of patent-expired Forxiga (dapagliflozin), new drug enavogliflozin, and other combo drugs will hit the market next month. (Credit: Getty Images) The Ministry of ...
These effects on intravascular volume and blood pressure will result in reduced preload and afterload respectively, thereby facilitating the positive remodelling of the heart [41, 42]. This effect of SGLT2 inhibitors on positive LV remodelling will have major implications on morbidity and mortality in...
Second, all patients were enrolled at sites in the United States and, while this makes the study applicable to the US population with HFpEF, its generalizability outside that country is uncertain. Additional data from global trials of SGLT2 inhibitors, including the recently completed EMPEROR-...
work of other groups indicating a potential dependence of irradiated cells on mitochondrial respiration51. This could result in a specific sensitivity of irradiated cells to mitochondrial inhibitors and the generation of a niche for synthetic lethality when OxPhos inhibitors are combined with radiotherapy...
Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025–9. Article PubMed Google Scholar Packer M. Autophagy-dependent and -independent modulation of oxidative and organellar ...
This was achieved by searching each medicinal plant from the generated list for their potential incretin modulatory and SGLT2 inhibitory activity. Search strings such as “name of the medicinal plants and/or SGLT2 inhibitors”, “name of the medicinal plants and DPP-IV inhibitors”, “name of ...
Overall, in a manner similar to sulfonylureas, the glitazones have not shown a clear cardiovascular or renal benefit, and carry a less-than-ideal side-effect profile than either metformin or the sulfonylureas. Dipeptidyl Peptidase 4 Inhibitors DPP4i (Figure 4) modulate the incretin pathway, a ...
Long-term clinical studies on the incidence of microvascular complications, such as diabetic nephropa- thy, are ongoing and will determine whether SGLT2 inhibitors exert benefits that are superior to traditional agents13. While we were unable to show considerable improvements in renal function, the ...
Sodium-dependent glucose transporter (SGLT)-2 inhibitors, a new anti-diabetic strategy, target the renal proximal tubules to block glucose reabsorption, thereby enhancing urinary glucose excretion and conferring anti-hyperglycemic effects. They are indicated for use in individuals with type 2 diabetes (...